

Opto Circuits (India) Ltd. subsidiary Eurocor GmbH presents very convincing clinical results from the DIOR® DEBUIT Trial

Paris | Bonn | May 28, 2010

Dr. Peter Stella, Principal Investigator for the DEBUIT Multi-center Clinical Study, on May 26th 2010 presented late breaking results involving the Eurocor drug-eluting balloon catheter (DEB) at the EuroPCR Conference in Paris, France. EuroPCR is the official congress of the European Association of Percutaneous Cardiovascular Interventions (EAPCI), and is the leading annual course contributing to the advancement of education and information in the field of percutaneous coronary interventions which attracts over 11,500 attendees from the four corners of the globe.

The results were presented as part of late-breaking trial results selected annually by the EuroPCR. The study compared the effectiveness of the Eurocor DIOR® DEB device in combination with a bare metal stent (BMS) vs. other treatment options involving drug-eluting stents and uncoated balloon catheters.

The study results as presented clearly show very strong and significant clinical advantages provided by the DIOR® DEB in bifurcated lesions with significantly reduced rates of binary restenosis as well as lower rates for MACE, TLR and TVR. The randomized study adds to the growing set of clinical data that documents significant and lasting clinical advantages delivered by the use of the Eurocor DIOR® Drug coated Dilatation Catheter.

“Having launched the first CE-marked drug-eluting balloon catheter over two years ago, Opto’s subsidiary Eurocor is a clear leader and innovator in this novel device space”, says Vinod Ramnani, Chairman and Managing Director of Opto Circuits (India) Ltd.” We are very pleased to hear that this fully randomized multi-center clinical study has validated our vision and belief in the DIOR® DEB device”, he continued.

The DIOR® DEB is used to treat the narrowing and calcifications of coronary arteries and is specifically designed to improve outcomes in in-stentrestenosis (ISR), bifurcated lesions and small vessels.

Used independently or in combination with a bare metal stent, the DIOR® DEB delivers a low-risk and cost-effective alternative to the well known drug-eluting stents (DES) in use for several years now.

A further advantage of the DIOR® device is that the regiment of blood-thinners required after the procedure is reduced to 90 days in comparison to 12 months or more that is required after stenting with a drug-eluting stent.